Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NAUT Stock Forecast 2026-2027
$1.64
Current Price
$222.39M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NAUT Price Targets
+143.9%
To High Target of $4.00
+143.9%
To Median Target of $4.00
+143.9%
To Low Target of $4.00
NAUT Price Momentum
-13.2%
1 Week Change
-24.8%
1 Month Change
+121.6%
1 Year Change
-15.9%
Year-to-Date Change
-61.9%
From 52W High of $4.31
+164.5%
From 52W Low of $0.62
📊 TOP ANALYST CALLS
Did NAUT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Nautilus is one of their latest high-conviction picks.
Latest NAUT Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, NAUT has a bullish consensus with a median price target of $4.00 (ranging from $4.00 to $4.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $1.64, the median forecast implies a 143.9% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Subbu Nambi at Guggenheim, projecting a 143.9% upside. Conversely, the most conservative target is provided by Subbu Nambi at Guggenheim, suggesting a 143.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NAUT Analyst Ratings
2
Buy
0
Hold
0
Sell
NAUT Price Target Range
Low
$4.00
Average
$4.00
High
$4.00
Current: $1.64
Latest NAUT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NAUT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 27, 2026 | Guggenheim | Subbu Nambi | Buy | Maintains | $4.00 |
| Dec 5, 2024 | Goldman Sachs | Sell | Downgrade | $N/A | |
| Jun 27, 2024 | Guggenheim | Buy | Initiates | $N/A | |
| Jun 3, 2024 | Jefferies | Tycho Peterson | Hold | Assumes | $3.00 |
| Aug 3, 2023 | Morgan Stanley | Equal-Weight | Reiterates | $N/A | |
| Aug 3, 2022 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Aug 3, 2022 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Jul 14, 2022 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Apr 13, 2022 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Jan 6, 2022 | Morgan Stanley | Equal-Weight | Initiates | $N/A | |
| Nov 2, 2021 | Cowen & Co. | Outperform | Initiates | $N/A | |
| Aug 4, 2021 | Goldman Sachs | Neutral | Initiates | $N/A | |
| Jul 13, 2021 | Jefferies | Buy | Initiates | $N/A |
Nautilus Biotechnology, Inc. (NAUT) Competitors
The following stocks are similar to Nautilus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Nautilus Biotechnology, Inc. (NAUT) Financial Data
Nautilus Biotechnology, Inc. has a market capitalization of $222.39M with a P/E ratio of -3.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -33.7%.
Valuation Metrics
Market Cap
$222.39M
Enterprise Value
$173.18M
P/E Ratio
-3.7x
PEG Ratio
0.5x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+46.0%
Current Ratio
11.8x
Debt/Equity
20.0x
ROE
-33.7%
ROA
-19.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Nautilus Biotechnology, Inc. (NAUT) Business Model
About Nautilus Biotechnology, Inc.
What They Do
Develops technology for analyzing the human proteome.
Business Model
Nautilus Biotechnology generates revenue through its Nautilus Platform, which offers an integrated solution comprising instruments, consumables, and software for proteomic analysis. The company also runs an Early Access Program that provides select researchers with exclusive access to its technology and custom assay development, facilitating collaborative research in key areas such as neurodegenerative diseases.
Additional Information
Founded in 2016 and headquartered in Seattle, Nautilus Biotechnology is focused on leveraging its advanced platforms to drive innovations in human health, particularly in the study of Alzheimer's disease and other neurodegenerative conditions. Collaborations with prestigious institutions bolster its research capabilities and market presence.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
127
CEO
Mr. Sujal M. Patel
Country
United States
IPO Year
2021
Website
www.nautilus.bioNautilus Biotechnology, Inc. (NAUT) Latest News & Analysis
Latest News
Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
8 days ago
Quick Summary
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will report Q2 2026 financial results on July 28, 2026, before market open, followed by a conference call at 5:30 a.m.
Why It Matters
Nautilus Biotechnology's upcoming financial results may reveal performance trends and growth potential, influencing investor sentiment and stock valuation ahead of the report.
Source: GlobeNewsWire
Market Sentiment:
Neutral
3 Small-Cap Stocks to Buy Before May 15
2 months ago
Quick Summary
Rate cuts in 2026 could benefit smaller companies, presenting potential investment opportunities in that sector.
Why It Matters
Potential rate cuts in 2026 could enhance borrowing conditions and profitability for smaller companies, influencing their growth prospects and attractiveness to investors.
Source: InvestorPlace
Market Sentiment:
Positive
Quick Summary
Nautilus Biotechnology, Inc. (NAUT) held its Q1 2026 earnings call, detailing financial performance and strategic updates for investors. Further specifics on earnings were not provided in the excerpt.
Why It Matters
The Q1 2026 earnings call provides insights into Nautilus Biotechnology's financial performance and strategic direction, impacting stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Nautilus Biotechnology (NASDAQ: NAUT) reported Q1 2026 results, highlighting the launch of its Iterative Mapping Early Access Program and securing Baylor College of Medicine as a customer for its Tau proteoform assay.
Why It Matters
Nautilus Biotechnology's Q1 results and new early access program signal growth potential and market validation, especially in cancer research, which may boost investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Baylor has chosen the Nautilus Voyager™ Platform for developing a multi-omics toolkit, focusing on high-resolution cancer isoform analysis in a NIH-funded project.
Why It Matters
The selection of the Nautilus Voyager™ Platform for cancer research indicates potential breakthroughs in multi-omics tools, which could enhance biotech investments and drive innovation in personalized medicine.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Nautilus Biotechnology, Inc. (NAUT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
4 months ago
Quick Summary
Nautilus Biotechnology, Inc. (NAUT) presented at the TD Cowen 46th Annual Health Care Conference, discussing its developments and strategies in the biotechnology sector.
Why It Matters
Nautilus Biotechnology's presentation at a major conference can signal potential growth or innovation, influencing investor sentiment and stock performance in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About NAUT Stock
What is Nautilus Biotechnology, Inc.'s (NAUT) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Nautilus Biotechnology, Inc. (NAUT) has a median price target of $4.00. The highest price target is $4.00 and the lowest is $4.00.
Is NAUT stock a good investment in 2027?
According to current analyst ratings, NAUT has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.64. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NAUT stock?
Wall Street analysts predict NAUT stock could reach $4.00 in the next 12 months. This represents a 143.9% increase from the current price of $1.64. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nautilus Biotechnology, Inc.'s business model?
Nautilus Biotechnology generates revenue through its Nautilus Platform, which offers an integrated solution comprising instruments, consumables, and software for proteomic analysis. The company also runs an Early Access Program that provides select researchers with exclusive access to its technology and custom assay development, facilitating collaborative research in key areas such as neurodegenerative diseases.
What is the highest forecasted price for NAUT Nautilus Biotechnology, Inc.?
The highest price target for NAUT is $4.00 from Subbu Nambi at Guggenheim, which represents a 143.9% increase from the current price of $1.64.
What is the lowest forecasted price for NAUT Nautilus Biotechnology, Inc.?
The lowest price target for NAUT is $4.00 from Subbu Nambi at Guggenheim, which represents a 143.9% increase from the current price of $1.64.
What is the overall NAUT consensus from analysts for Nautilus Biotechnology, Inc.?
The overall analyst consensus for NAUT is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are NAUT stock price projections?
Stock price projections, including those for Nautilus Biotechnology, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:55 AM UTC